FGFR2 and breast cancer: Apart from breast cancer, 10–12% of endometrial carcinoma and 4–5% of NSCLCs bear FGFR2 mutations (Mohammadi et al., 1998; Dutt et al., 2008; Kandoth et al., 2013).